Bli medlem
Bli medlem

Du är här


Galapagos NV: Galapagos raises €5.8 million through warrant exercises, Board and Executive Committee members invest

Mechelen, Belgium; 27 March 2015 - Galapagos NV (Euronext: GLPG) announced
today a share capital increase arising from warrant exercises. Board members
invest €2.1 million in Galapagos by exercising warrants.

Since its inception in 1999, Galapagos has used warrant plans to incentivize
personnel and management and have them share in the success of the company.
Following warrant exercises during the exercise period from 9 March 2015
through 22 March 2015, Galapagos issued 571,548 new ordinary shares for a
total capital increase (including issuance premium) of €5,819,033.48.

CEO Onno van de Stolpe exercised 100,000 warrants to hold as shares. Onno van
de Stolpe currently holds 464,226 shares in Galapagos, representing 1.5% of
the outstanding Galapagos shares. The Chairman of the Board of Directors, Dr
Raj Parekh, exercised 75,000 warrants to hold as shares. In addition, Board
members Dr Werner Cautreels and Dr Harrold van Barlingen exercised 2,520
warrants and 7,500 warrants, respectively, also to hold as shares. Together,
the CEO and the other Board members invested €2.1 million in Galapagos by
exercising these warrants with an exercise price of €11.55 per share. All of
these warrants were due to expire on 26 April 2015.

Dr Piet Wigerinck and Dr Andre Hoekema of the Executive Committee exercised an
aggregate number of 5,000 warrants to hold as shares under the Galapagos'
Executive Committee warrant exercise program whereby members have made a
commitment to exercise a minimum number of warrants during subsequent
exercise periods, subject to certain conditions.

To date, Galapagos' total share capital amounts to €166,996,209.57; the total
number of securities conferring voting rights is 30,870,677, which is also
the total number of voting rights (the "denominator"), and all securities
conferring voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued securities
conferring voting rights is 3,019,305, which equals the total number of
voting rights that may result from the exercise of these warrants. Galapagos
does not have any convertible bonds or shares without voting rights

About Galapagos

Galapagos(Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology
company specialized in the discovery and development of small molecule
medicines with novel modes of action, with a pipeline comprising three Phase
2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation, and
other indications. In the field of inflammation, AbbVie and Galapagos signed
a collaboration agreement for the development and commercialization
offilgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. GLPG1205,a first-in-class inhibitor of GPR84, is currently being
tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a first-in-class inhibitor of autotaxin,has shown favorable safety
in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary
fibrosis. AbbVie and Galapagos also signed a collaboration agreement in
cystic fibrosis to develop and commercialize molecules that address mutations
in the CFTR gene. PotentiatorGLPG1837is currently in a Phase 1 trial, and
corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos
Group, including fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and facilities
in The Netherlands, France, and Croatia. Further information


Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications&IR
Tel: +31 6 2291 6240

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without
limitation, expectations regarding the commercial potential of our product
candidates generally, all of which involve certain risks and uncertainties.
These statements are often, but are not always, made through the use of words
or phrases such as "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Among the factors that may result in differences
are the inherent uncertainties associated with competitive developments,
clinical trial and product development activities, regulatory approval
requirements and estimating the commercial potential of our product
candidates. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.